KLRS Kalaris Therapeutics Inc.
- Stocks
- Healthcare
- NASDAQ: KLRS
Price (delayed)
$5
Market cap
$93.51M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$7.73
Enterprise value
$4.59M
Relative Growth:
Rel. Growth:
24
Relative Strength:
Rel. Strength:
64
Relative Valuation:
Rel. Valuation:
N/A
Relative Profitability:
Rel. Profitability:
11
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The
Highlights
Kalaris Therapeutics's debt has plunged by 100% YoY
KLRS's EPS has soared by 72% YoY and by 32% QoQ
The net income has soared by 61% year-on-year but it is down by 15% since the previous quarter
The quick ratio has dropped by 79% year-on-year and by 18% since the previous quarter
The equity has dropped by 56% year-on-year and by 17% since the previous quarter
Key stats
What are the main financial stats of KLRS
Market
Valuations
Earnings
Shares outstanding
18.7M
Market cap
$93.51M
Enterprise value
$4.59M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.76
Price to sales (P/S)
N/A
PEG
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$47.98M
Net income
-$43.94M
EBIT
-$42.5M
EBITDA
-$42.5M
Free cash flow
-$31.99M
Per share
Balance sheet
Liquidity
EPS
-$7.73
EPS diluted
-$7.73
Free cash flow per share
-$1.71
Book value per share
$2.84
Revenue per share
$0
TBVPS
$4.96
Total assets
$92.84M
Total liabilities
$39.73M
Debt
$0
Equity
$53.12M
Working capital
$84M
Debt to equity
0
Current ratio
11.98
Quick ratio
11.62
Net debt/EBITDA
2.09
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-54.1%
Return on equity
-124.2%
Return on invested capital
N/A
Return on capital employed
-49.9%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
KLRS stock price
How has the Kalaris Therapeutics stock price performed over time
Intraday
6.16%
1 week
2.67%
1 month
-24.7%
1 year
-78.04%
YTD
-48.24%
QTD
-13.49%
Financial performance
How have Kalaris Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$47.98M
Net income
-$43.94M
Gross margin
N/A
Net margin
N/A
The net income has soared by 61% year-on-year but it is down by 15% since the previous quarter
The operating income has soared by 59% YoY but it has contracted by 20% from the previous quarter
Price vs fundamentals
How does KLRS's price correlate with its fundamentals
Growth
What is Kalaris Therapeutics's growth rate over time
Valuation
What is Kalaris Therapeutics stock price valuation
P/E
N/A
P/B
1.76
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
KLRS's EPS has soared by 72% YoY and by 32% QoQ
The equity has dropped by 56% year-on-year and by 17% since the previous quarter
The price to book (P/B) is 27% less than the 5-year quarterly average of 2.4
Efficiency
How efficient is Kalaris Therapeutics business performance
KLRS's return on equity has dropped by 69% since the previous quarter and by 60% year-on-year
The return on assets has declined by 28% since the previous quarter but it rose by 15% year-on-year
Dividends
What is KLRS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for KLRS.
Financial health
How did Kalaris Therapeutics financials performed over time
The total assets is 134% greater than the total liabilities
The quick ratio has dropped by 79% year-on-year and by 18% since the previous quarter
The current ratio has plunged by 78% YoY and by 16% from the previous quarter
Kalaris Therapeutics's debt is 100% less than its equity
KLRS's debt to equity has dropped by 100% year-on-year
Kalaris Therapeutics's debt has plunged by 100% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.